Ranbaxy Makes “Practical” Bid For Merck KGaA’s Generics Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Singh maintains that the Indian generic drug company is not in a “rat race.”
You may also be interested in...
Ranbaxy Strengthens Ties With Injectables Specialist Zenotech
Expanded investment will help Ranbaxy’s position in the specialty sector, firm says; the two Indian companies have already collaborated on development of a biosimilar.
Ranbaxy Strengthens Ties With Injectables Specialist Zenotech
Expanded investment will help Ranbaxy’s position in the specialty sector, firm says; the two Indian companies have already collaborated on development of a biosimilar.
Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA’s Generics Unit
Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.